Other relevant information about the company follows: The 20-year Treasury Bond rate is currently 4.5 percent and you have estimated market-risk premium to be 6.75 percent using the returns on stocks and Treasury bonds from 2010 to 2019. Pharmos Incorporated has a marginal tax rate of 25 percent. Based on the statement is the photos attached and above, asnwer the following question Determine the initial outlay of the project. Calculate the annual after-tax operating cash flow for Years 1 -5.
Other relevant information about the company follows: The 20-year Treasury Bond rate is currently 4.5 percent and you have estimated market-risk premium to be 6.75 percent using the returns on stocks and Treasury bonds from 2010 to 2019. Pharmos Incorporated has a marginal tax rate of 25 percent. Based on the statement is the photos attached and above, asnwer the following question Determine the initial outlay of the project. Calculate the annual after-tax operating cash flow for Years 1 -5.
Excel Applications for Accounting Principles
4th Edition
ISBN:9781111581565
Author:Gaylord N. Smith
Publisher:Gaylord N. Smith
Chapter26: Capital Budgeting (capbud)
Section: Chapter Questions
Problem 5R
Related questions
Question
Other relevant information about the company follows:
The 20-year Treasury Bond rate is currently 4.5 percent and you have estimated market-risk premium to be 6.75 percent using the returns on stocks and Treasury bonds from 2010 to 2019. Pharmos Incorporated has a marginal tax rate of 25 percent.
Based on the statement is the photos attached and above, asnwer the following question
- Determine the initial outlay of the project.
- Calculate the annual after-tax operating cash flow for Years 1 -5.
![The company will contract a new loan in the sum of $2,000,000 that is secured by
machinery and the loan has an interest rate of 6 percent. Pharmos Incorporated has also
issued 4,000 new bond issues with an 8 percent coupon, paid semi-annually, and
matures in 10 years. The bonds were sold at par, and incurred floatation cost of 2
percent per issue.
The company's preferred stock pays an annual dividend of 4.5 percent and is currently
selling for $60, and there are 100,000 shares outstanding.
• There are 300,000 shares of common stock outstanding, and they are currently selling
for $21 each. The beta on these shares is 0.95.](/v2/_next/image?url=https%3A%2F%2Fcontent.bartleby.com%2Fqna-images%2Fquestion%2Fdcc1a9f2-feca-4634-abfe-dd6255893ee3%2Fbd51cab8-f0f3-4e0a-b484-a1e6f040e15d%2F1efzvxf_processed.jpeg&w=3840&q=75)
Transcribed Image Text:The company will contract a new loan in the sum of $2,000,000 that is secured by
machinery and the loan has an interest rate of 6 percent. Pharmos Incorporated has also
issued 4,000 new bond issues with an 8 percent coupon, paid semi-annually, and
matures in 10 years. The bonds were sold at par, and incurred floatation cost of 2
percent per issue.
The company's preferred stock pays an annual dividend of 4.5 percent and is currently
selling for $60, and there are 100,000 shares outstanding.
• There are 300,000 shares of common stock outstanding, and they are currently selling
for $21 each. The beta on these shares is 0.95.
![Pharmos Incorporated is a Pharmaceutical Company which is considering investing in a new
production line of portable electrocardiogram (ECG) machines for its clients who suffer from
cardiovascular diseases. The company must invest in equipment which cost $2,500,000 and falls
within a MARCS depreciation of 5-years and is expected to have a scrape value of $200,000 at|
the end of the project. Other than the equipment, the company needs to increase its cash and
cash equivalents by $100,000, increase the level of inventory by $30,000, increase accounts
receivable by $250,000 and increase account payable by $50,000 at the beginning of the
project. Pharmos Incorporated expect the project to have a life of five years. The company
would have to pay for transportation and installation of the equipment which has an invoice
price of $450,000o.
The company has already invested $75,000 in Research and Development and therefore
expects a positive impact on the demand for the new product line. Expected annual sales for
the ECG machines in the first three years are $1,200,000 and $850,000 in the following two
years. The variable costs of production are projected to be $267,000 per year in years one to
three and $375,000 in years four and five. Fixed overhead is $180,000 per year over the life of
the project.
The introduction of the new line of portable ECG machines will cause a net decrease of $50,000
in profit, EACH YEAR in contribution after taxes, due to a decrease in sales of the other lines of
tester machines produced by the company. By investing in the new product line Pharmos
Incorporated would have to use a packaging machine which the company already has and will
be sold at the end of the project for $350,000 after-tax in the equipment market.](/v2/_next/image?url=https%3A%2F%2Fcontent.bartleby.com%2Fqna-images%2Fquestion%2Fdcc1a9f2-feca-4634-abfe-dd6255893ee3%2Fbd51cab8-f0f3-4e0a-b484-a1e6f040e15d%2Fbfkuhk_processed.jpeg&w=3840&q=75)
Transcribed Image Text:Pharmos Incorporated is a Pharmaceutical Company which is considering investing in a new
production line of portable electrocardiogram (ECG) machines for its clients who suffer from
cardiovascular diseases. The company must invest in equipment which cost $2,500,000 and falls
within a MARCS depreciation of 5-years and is expected to have a scrape value of $200,000 at|
the end of the project. Other than the equipment, the company needs to increase its cash and
cash equivalents by $100,000, increase the level of inventory by $30,000, increase accounts
receivable by $250,000 and increase account payable by $50,000 at the beginning of the
project. Pharmos Incorporated expect the project to have a life of five years. The company
would have to pay for transportation and installation of the equipment which has an invoice
price of $450,000o.
The company has already invested $75,000 in Research and Development and therefore
expects a positive impact on the demand for the new product line. Expected annual sales for
the ECG machines in the first three years are $1,200,000 and $850,000 in the following two
years. The variable costs of production are projected to be $267,000 per year in years one to
three and $375,000 in years four and five. Fixed overhead is $180,000 per year over the life of
the project.
The introduction of the new line of portable ECG machines will cause a net decrease of $50,000
in profit, EACH YEAR in contribution after taxes, due to a decrease in sales of the other lines of
tester machines produced by the company. By investing in the new product line Pharmos
Incorporated would have to use a packaging machine which the company already has and will
be sold at the end of the project for $350,000 after-tax in the equipment market.
Expert Solution
![](/static/compass_v2/shared-icons/check-mark.png)
Step 1
Capital budgeting is a technique that helps to check weather the project will be beneficial for company or not.
Step 2
The calculation is shown:
Formulation:
Step by step
Solved in 3 steps with 4 images
![Blurred answer](/static/compass_v2/solution-images/blurred-answer.jpg)
Knowledge Booster
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, finance and related others by exploring similar questions and additional content below.Recommended textbooks for you
![Excel Applications for Accounting Principles](https://www.bartleby.com/isbn_cover_images/9781111581565/9781111581565_smallCoverImage.gif)
Excel Applications for Accounting Principles
Accounting
ISBN:
9781111581565
Author:
Gaylord N. Smith
Publisher:
Cengage Learning
![EBK CONTEMPORARY FINANCIAL MANAGEMENT](https://www.bartleby.com/isbn_cover_images/9781337514835/9781337514835_smallCoverImage.jpg)
EBK CONTEMPORARY FINANCIAL MANAGEMENT
Finance
ISBN:
9781337514835
Author:
MOYER
Publisher:
CENGAGE LEARNING - CONSIGNMENT
![Cornerstones of Cost Management (Cornerstones Ser…](https://www.bartleby.com/isbn_cover_images/9781305970663/9781305970663_smallCoverImage.gif)
Cornerstones of Cost Management (Cornerstones Ser…
Accounting
ISBN:
9781305970663
Author:
Don R. Hansen, Maryanne M. Mowen
Publisher:
Cengage Learning
![Excel Applications for Accounting Principles](https://www.bartleby.com/isbn_cover_images/9781111581565/9781111581565_smallCoverImage.gif)
Excel Applications for Accounting Principles
Accounting
ISBN:
9781111581565
Author:
Gaylord N. Smith
Publisher:
Cengage Learning
![EBK CONTEMPORARY FINANCIAL MANAGEMENT](https://www.bartleby.com/isbn_cover_images/9781337514835/9781337514835_smallCoverImage.jpg)
EBK CONTEMPORARY FINANCIAL MANAGEMENT
Finance
ISBN:
9781337514835
Author:
MOYER
Publisher:
CENGAGE LEARNING - CONSIGNMENT
![Cornerstones of Cost Management (Cornerstones Ser…](https://www.bartleby.com/isbn_cover_images/9781305970663/9781305970663_smallCoverImage.gif)
Cornerstones of Cost Management (Cornerstones Ser…
Accounting
ISBN:
9781305970663
Author:
Don R. Hansen, Maryanne M. Mowen
Publisher:
Cengage Learning